Although therapeutic GC-C agonists have been extensively studied in the treatment of irritable bowel syndrome and chronic constipation, additional studies focusing on the impact of GC-C agonists on the bacterial microflora of the bowel, pathogenic or otherwise, is warranted20. Here, GUCY2C is linked to irritable bowel syndrome.